Molecular Partners AG MOLN
Molecular Partners AG (Nasdaq: MOLN) is an oncology drug developer. Its lead program, MP0317, is in Phase 2 for first-line advanced biliary tract carcinoma / cholangiocarcinoma (with durvalumab + gemcitabine-cisplatin). Its next catalyst on record is MP0726: First-in-human imaging start (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: MP0726 — First-in-human imaging start (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MP0317 (FAP-localized CD40 agonist DARPin) | cholangiocarcinoma (Phase 2 TACTIC); advanced solid tumors (Phase 1 completed) | protein/peptide | Phase 2 |
| MP0712 (212Pb DLL3 Radio-DARPin, with Orano Med) | small cell lung cancer and neuroendocrine cancers | radiopharmaceutical | Phase 1 |
| MP0533 | oncology (DARPin) | protein/peptide | Phase 1 |
| MP0726 (MSLN Radio-DARPin) | mesothelin-expressing cancers such as ovarian | radiopharmaceutical | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.